Alzheimer’s imaging pact
This article was originally published in The Gray Sheet
Executive Summary
Drug-diagnostic giant Bayer Schering licenses an Alzheimer's-detecting positron emission tomography agent from Philadelphia molecular imaging firm Avid Radiopharmaceuticals. The deal, announced June 19, results from a 2005 option agreement between the two companies for AV1/ZK and related fluorine-based compounds, which target amyloid plaques in the brain...